Breast Cancer Tumor Care Observational Programme

The purpose of this study is to investigate efficacy and tolerability under anastrozole (Arimidex) treatment.

Completed

Looking for future studies?

Key information

Conditions

Post Menopausal Arthralgia Joint Diseases Musculoskeletal Diseases Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Sex eligibility

Female

Study type

Observational

Primary location

Research Site

Graz, Austria

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Postmenopausal women
Already on upfront Arimidex Therapy (Start 1-4 weeks before)
HR+

Exclusion criteria

Premenopausal women
Tamoxifen switch patients

Treatment and study plan

Anastrozole

Drug

Oral

Other names: Arimidex

Primary outcomes

Progression of disease and tolerability in general

Time frame: Baseline, every 3 month

Secondary outcomes

Patient questionnaire to collect data on Incidence, time of onset and treatment of arthralgia

Time frame: Baseline, every 3 month

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Breast Cancer Tumor Care Patient Observation Programme

Important dates

Study start: 2008
Study completion: 2009
First posted: Apr 17, 2008
Registry last updated: Jun 6, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed